Mario H Skiadopoulos
Overview
Explore the profile of Mario H Skiadopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White R, Kovacs G, Chandran S, Adams P, Britson K, Cao H, et al.
Health Secur
. 2025 Jan;
23(1):47-54.
PMID: 39882823
The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat,...
2.
Finch C, Dowling W, King T, Martinez C, Nguyen B, Roozendaal R, et al.
Vaccines (Basel)
. 2022 Sep;
10(9).
PMID: 36146462
The FDA Animal Rule was devised to facilitate approval of candidate vaccines and therapeutics using animal survival data when human efficacy studies are not practical or ethical. This regulatory pathway...
3.
Finch C, Martinez C, Leffel E, Skiadopoulos M, Hacker A, Mwesigwa B, et al.
Vaccines (Basel)
. 2022 Mar;
10(3).
PMID: 35335000
Clinical vaccine development and regulatory approval generally occurs in a linear, sequential manner: Phase 1: safety, immunogenicity; Phase 2: immunogenicity, safety, dose ranging, and preliminary efficacy; Phase 3: definitive efficacy,...
4.
Mytle N, Leyrer S, Inglefield J, Harris A, Hickey T, Minang J, et al.
Viruses
. 2021 Sep;
13(9).
PMID: 34578289
Influenza hemagglutinin (HA) is considered a major protective antigen of seasonal influenza vaccine but antigenic drift of HA necessitates annual immunizations using new circulating HA versions. Low variation found within...
5.
Shearer J, Henning L, Sanford D, Li N, Skiadopoulos M, Reece J, et al.
Vaccine
. 2020 Nov;
39(1):1-5.
PMID: 33199078
The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or...
6.
Perry M, Ionin B, Barnewall R, Vassar M, Reece J, Park S, et al.
Vaccine
. 2020 Feb;
38(10):2307-2314.
PMID: 32029323
A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax...
7.
Savransky V, Lacy M, Ionin B, Skiadopoulos M, Shearer J
Int J Toxicol
. 2019 Jun;
38(3):163-172.
PMID: 31179828
A recombinant protective antigen (rPA) anthrax vaccine candidate (rPA7909) was developed as a next-generation vaccine indicated for postexposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The...
8.
Efficacy of atropine sulfate/obidoxime chloride co-formulation against sarin exposure in guinea pigs
Joosen M, Klaassen S, Verheij E, van Groningen T, Cornelissen A, Skiadopoulos M, et al.
Chem Biol Interact
. 2018 Sep;
296:34-42.
PMID: 30217478
The efficacy and pharmacokinetics of the aqueous co-formulation contents of the Trobigard™ (atropine sulfate, obidoxime chloride) auto-injector were evaluated in a sarin exposed guinea pig model. Two subcutaneous (sc) sarin...
9.
Savransky V, Shearer J, Gainey M, Sanford D, Sivko G, Stark G, et al.
Vaccine
. 2017 Aug;
35(37):4952-4959.
PMID: 28774566
The anthrax vaccine candidate AV7909 is being developed as a next generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA, BioThrax®)...
10.
Longstreth J, Skiadopoulos M, Hopkins R
Expert Rev Vaccines
. 2016 Oct;
15(12):1467-1479.
PMID: 27792416
The availability of a licensed anthrax vaccine that is safe, effective, and easy to administer for both pre- and post-exposure prophylaxis is critical to successfully manage and prevent potential anthrax...